Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyltransferase 2B, tRNA N3-cytidine (METTL2B) is a protein-coding gene in humans located on chromosome 7[2][4]. It encodes an S-adenosyl-L-methionine-dependent methyltransferase that catalyzes the N(3)-methylcytidine modification of residue 32 in the anticodon loop of specific tRNA species, including tRNA(Thr)(UGU) and tRNA(Arg)(CCU)[2][3][4]. This modification is implicated in the fine-tuning of translation and maintains the structure and function of certain tRNAs[2][3]. METTL2B is part of a larger family of methyltransferases that primarily act on RNA targets, distinguishing it from DNA or protein methyltransferases[1]. METTL2B is expressed in the cytoplasm, functions alongside highly similar paralogs (notably METTL2A), and exhibits lower tRNA methylation activity compared to METTL2A due to specific amino acid differences influencing its enzymatic activity[3]. Although METTL2B has no well-established direct disease associations or targeted therapeutics, it represents an important component of the cellular RNA modification machinery, contributing to epitranscriptomic regulation[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyltransferase 2B, tRNA N3-cytidine (METTL2B).